Venetoclax plus azacitidine as a bridge treatment to allogeneic stem cell transplantation in acute myeloid leukaemia patients

Abstract

Allogeneic hematopoietic cell transplantation is the most effective form of consolidation therapy for patients with acute myeloid leukemia. The combination of venetoclax and azacitidine represents an alternative to initial therapy with lower toxicity and high rate of achieved remissions, enabling subsequent transplantation even in patients initially unsuitable for intensive therapy. The article describes the possibilities of using the combination of venetoclax and azacitidine as a bridge to allogeneic hematopoietic cell transplantation.